CDKN2A and non-small cell lung carcinoma: Interestingly, patients with CDKN2A mutations in our cohort were more likely to experience disease progression during treatment and, consequently, had significantly poorer OS, consistent with observations in other cancers, such as non-small cell lung cancer (NSCLC) [32].